Clinical trial
Patient's Perception of Treatment Outcome With Darifenacin by Patients With…
NCT00366002 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00366002 |
|---|---|
| Title | Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder |
| Official title | A 12-Week, Open-Label, Non-Randomized, Multicenter Study to Evaluate the Patient's Perception of Outcome After Treatment With Darifenacin in Overactive Bladder (OAB) Patients Dissatisfied With Prior Anticholinergic Therapy |
| Lead sponsor | Novartis, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Overactive Bladder (OAB) |
| Intervention type | Drug |
| Interventions | Darifenacin |
| Enrollment | 500 |
| Start date | Jun 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Aug 18, 2006 |
| Last update posted | Jan 15, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: